NVO - Escalating Demand for Obesity Drugs Creates Time-Sensitive Race for Eli Lilly Novo Nordisk | Benzinga
Eli Lilly (NYSE:LLY) is aggressively pursuing collaborations with outsourcing partners to ramp up the production of its obesity drug, Zepbound (tirzepatide), as it inks deals with key players such as National Resilience and BSP Pharmaceuticals for the filling and “finishing” of its injector pens.
BSP Pharmaceuticals and National Resilience are among the specialized contract manufacturers capitalizing on the obesity drug boom.
The global contract development and manufacturing market is poised to grow from $72 billion to $90 billion in the next two years, highlighting the urgency for increased fill-finish capacity.
Also Read: Eli Lilly’s Commercial Moat, Competitor Landscape: BofA Emphasizes Strength in Incretin ...